Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The First Affiliated Hospital of Soochow University
Pfizer
Children's Oncology Group
St. Jude Children's Research Hospital
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
First Affiliated Hospital of Zhejiang University
Institute of Hematology & Blood Diseases Hospital, China